Report of Foreign Issuer (6-k)
May 09 2017 - 4:12PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May, 2017
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Other Events
On May 9, 2017, GW Pharmaceuticals plc
(the “Company”) issued a press release announcing its second quarter financial results and operational progress for
the quarter ended March 31, 2017 and details of a conference call to be held at 4:30 p.m. EST on May 9, 2017 to discuss the results
and operational progress. The press release is attached as Exhibit 99.1 and is incorporated by reference herein. The information
contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
Exhibits
99.1 Earnings Press
Release dated May 9, 2017
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
GW Pharmaceuticals plc
|
|
|
|
|
|
|
By:
|
/s/ Adam George
|
|
|
Name:
|
Adam George
|
|
|
Title:
|
Company Secretary
|
|
|
|
|
|
Date: May 9, 2017
|
|
|